About Retatrutide
Human randomized trial · Controlled study formulation
What it is studied for
A GIP, GLP-1 and glucagon receptor agonist studied in metabolic and body-weight research.
What selected research found
A 2023 phase 2 trial reported greater body-weight reduction than placebo; gastrointestinal adverse events were common.
Evidence limits
The trial does not validate this catalog material or establish its safety, identity, purity or suitability for human use.
Selected sources
References reviewed October 10, 2026.
Research use only. These notes summarize selected publications; they are not a systematic review, medical advice, dosing instructions, or evidence about this product lot. Clinical studies used controlled study formulations and supervision. AuraBio materials are not for human or veterinary use. Review the exact material identity and available lot documentation for your laboratory application.






Reviews
There are no reviews yet.